CY1120817T1 - Παραγωγα του αμυλοειδους ρ του ορου και η παρασκευη και χρηση τους - Google Patents

Παραγωγα του αμυλοειδους ρ του ορου και η παρασκευη και χρηση τους

Info

Publication number
CY1120817T1
CY1120817T1 CY181101079T CY181101079T CY1120817T1 CY 1120817 T1 CY1120817 T1 CY 1120817T1 CY 181101079 T CY181101079 T CY 181101079T CY 181101079 T CY181101079 T CY 181101079T CY 1120817 T1 CY1120817 T1 CY 1120817T1
Authority
CY
Cyprus
Prior art keywords
sap
human
modification
producers
manufacture
Prior art date
Application number
CY181101079T
Other languages
English (en)
Inventor
W Scott Willett
Richard J Caimi
Original Assignee
Promedior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc filed Critical Promedior Inc
Publication of CY1120817T1 publication Critical patent/CY1120817T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Μία άποψη της παρούσας εφεύρεσης σχετίζεται με την απροσδόκητη ανακάλυψη ότι η τροποποίηση μιας δομής γλυκάνης σε ένα ανθρώπινο SAP πολυπεπτίδιο μπορεί να αυξήσει τη βιολογική δραστικότητα του SAP πολυπεπτιδίου σε σχέση με ένα αντίστοιχο δείγμα αγρίου-τύπου SAP απομονωμένου από ανθρώπινο ορό. Η γνωστοποίηση παρέχει τόσο παραλλαγμένα ανθρώπινα SAP πολυπεπτίδια όσο και μεθόδους για παρασκευή τους. Πιο συγκεκριμένα, η παρούσα εφεύρεση παρέχει μεθόδους και συνθέσεις για in vitro και in vivo προσθήκη, διαγραφή ή τροποποίηση καταλοίπων σακχάρου για να παραχθούν SAP πολυπεπτίδια, όπως ένα ανθρώπινο SAP πολυπεπτίδιο, τα οποία έχουν ένα επιθυμητό πρότυπο γλυκοζυλίωσης.
CY181101079T 2009-06-04 2018-10-19 Παραγωγα του αμυλοειδους ρ του ορου και η παρασκευη και χρηση τους CY1120817T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21793109P 2009-06-04 2009-06-04
PCT/US2010/037542 WO2010141918A1 (en) 2009-06-04 2010-06-04 Serum amyloid p derivatives and their preparation and use
EP10784210.6A EP2438083B1 (en) 2009-06-04 2010-06-04 Serum amyloid p derivatives and their preparation and use

Publications (1)

Publication Number Publication Date
CY1120817T1 true CY1120817T1 (el) 2019-12-11

Family

ID=43298203

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101079T CY1120817T1 (el) 2009-06-04 2018-10-19 Παραγωγα του αμυλοειδους ρ του ορου και η παρασκευη και χρηση τους

Country Status (28)

Country Link
US (5) US9296800B2 (el)
EP (2) EP2438083B1 (el)
JP (3) JP5801293B2 (el)
CN (1) CN102574902B (el)
AU (1) AU2010256426B2 (el)
BR (2) BR122020010980B1 (el)
CA (1) CA2764461C (el)
CO (1) CO6480917A2 (el)
CR (1) CR20110640A (el)
CY (1) CY1120817T1 (el)
DK (2) DK2438083T3 (el)
EA (1) EA030332B1 (el)
ES (2) ES2692815T3 (el)
HK (1) HK1168603A1 (el)
HR (2) HRP20160221T1 (el)
HU (1) HUE026737T2 (el)
IL (1) IL216744A (el)
LT (1) LT3042915T (el)
MX (1) MX2011012738A (el)
MY (1) MY158761A (el)
NZ (1) NZ596849A (el)
PL (2) PL2438083T3 (el)
PT (1) PT3042915T (el)
SI (2) SI3042915T1 (el)
TR (1) TR201815592T4 (el)
UA (1) UA110323C2 (el)
WO (1) WO2010141918A1 (el)
ZA (1) ZA201108857B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
CA2755047C (en) 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
JP5797565B2 (ja) * 2009-03-11 2015-10-21 プロメディオール， インコーポレイテッド 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅ ｄｉｓｏｒｄｅｒ）に対する処置および診断方法
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
ES2552793T3 (es) 2009-06-17 2015-12-02 Promedior Inc. Variantes de SAP y su uso
FR2969153B1 (fr) * 2010-12-17 2014-10-17 Lab Francais Du Fractionnement Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee
WO2012158672A2 (en) 2011-05-16 2012-11-22 Polymedix, Inc. Compounds for use in treatment of mucositis
JP6340319B2 (ja) * 2011-12-21 2018-06-06 プロメディオール， インコーポレイテッド 血清アミロイドｐ−抗体融合タンパク質
EP3718558A1 (en) * 2013-10-08 2020-10-07 Promedior, Inc. Methods for treating fibrotic cancers
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
CN105372214B (zh) * 2014-08-18 2019-06-28 中国科学院上海有机化学研究所 一种鉴定新红细胞生成刺激蛋白的n-连接寡糖结构的方法
MX2019002734A (es) * 2016-09-13 2019-05-27 Bayer Healthcare Llc Glicoformas del factor viia.
JP6852397B2 (ja) 2016-12-28 2021-03-31 株式会社島津製作所 分析用試料の調製方法および分析方法
CN108114001B (zh) * 2017-12-23 2023-05-30 中国科学院海洋研究所 一种诱导海产双壳贝类产卵的诱导剂及其应用方法
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
IL302388A (en) * 2020-11-02 2023-06-01 Attralus Inc SAP FC fusion proteins and methods of use

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562244A (en) * 1976-11-11 1980-03-05 Lock P M Wound dressing materials
GB1594389A (en) * 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US6071517A (en) * 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
EP0321703B1 (en) * 1987-11-20 1993-04-28 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Absorbent for serum amyloid protein
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5092876A (en) * 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
EP0587777A4 (en) 1991-05-31 1995-05-10 New England Deaconess Hospital CARCINOBRYONARY ANTIGEN BINDING PROTEINS AND METHODS OF ISOLATING AND USING THE SAME.
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US6054121A (en) * 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
US5804446A (en) * 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
AU7043694A (en) 1993-05-27 1994-12-20 Regents Of The University Of Michigan, The Method of treatment and prevention of immune complex-induced lung injury
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5981470A (en) 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US6030815A (en) 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US5922577A (en) 1995-04-11 1999-07-13 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5876980A (en) 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US5728554A (en) 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
CA2204743C (en) * 1995-09-13 2008-09-02 Keiji Sakamoto D-pantolactone hydrolase and gene encoding the same
US5750345A (en) 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
AU712819B2 (en) 1996-01-25 1999-11-18 Profylakse Aps Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
AU8525098A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
IL137919A0 (en) * 1998-02-17 2001-10-31 Medarex Inc Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
DE99907899T1 (de) 1998-03-11 2005-01-13 Kabushiki Kaisha Soken Hautnormalisierungsmittel
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
JPH11319542A (ja) 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6600019B2 (en) * 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
EP1267795A1 (en) 2000-03-30 2003-01-02 Brennen Medical Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) * 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) * 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2004049214A (ja) 2001-11-29 2004-02-19 Nippon Shokubai Co Ltd 蛋白質またはペプチドの細胞内導入方法
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
US20050182042A1 (en) * 2002-05-17 2005-08-18 Feldman David L. Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
JP4819364B2 (ja) * 2002-12-23 2011-11-24 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物
US7763256B2 (en) * 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) * 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
US20070149450A1 (en) 2003-02-27 2007-06-28 Ranjit Bhardwaj Method for reducing levels of c-reactive protein
MXPA06011796A (es) 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
KR101297146B1 (ko) 2004-05-10 2013-08-21 마크로제닉스, 인크. 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법
WO2006002438A2 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)
WO2006002930A2 (en) 2004-06-30 2006-01-12 Friedrich-Alexander- Universitaet Erlangen- Nuernberg FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
ZA200701783B (en) 2004-09-02 2009-10-28 Genentech Inc Anti-Fc-gamma RIIB receptor antibody and uses therefor
US7553653B2 (en) * 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2006039418A2 (en) 2004-09-30 2006-04-13 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor ii (cd32)
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070243163A1 (en) 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
ES2554167T3 (es) 2007-07-06 2015-12-16 Promedior Inc. Métodos y composiciones útiles en el tratamiento de mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
JP5797565B2 (ja) * 2009-03-11 2015-10-21 プロメディオール， インコーポレイテッド 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅ ｄｉｓｏｒｄｅｒ）に対する処置および診断方法
CA2755047C (en) * 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
US20100266643A1 (en) 2009-04-01 2010-10-21 Willett W Scott Pulmonary and nasal delivery of serum amyloid p
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
ES2552793T3 (es) * 2009-06-17 2015-12-02 Promedior Inc. Variantes de SAP y su uso

Also Published As

Publication number Publication date
DK3042915T3 (en) 2018-11-05
HRP20181803T1 (hr) 2018-12-28
US20230058309A1 (en) 2023-02-23
CO6480917A2 (es) 2012-07-16
EA201171490A1 (ru) 2012-05-30
SI2438083T1 (sl) 2016-04-29
CA2764461C (en) 2021-05-04
EP3042915B1 (en) 2018-08-08
SI3042915T1 (sl) 2018-12-31
ES2692815T3 (es) 2018-12-05
TR201815592T4 (tr) 2018-11-21
EA030332B1 (ru) 2018-07-31
BRPI1012924B1 (pt) 2020-12-22
CN102574902A (zh) 2012-07-11
ZA201108857B (en) 2018-11-28
HRP20160221T1 (hr) 2016-03-25
ES2563748T3 (es) 2016-03-16
AU2010256426A1 (en) 2012-01-12
US20100317596A1 (en) 2010-12-16
US20180044387A1 (en) 2018-02-15
UA110323C2 (en) 2015-12-25
NZ596849A (en) 2013-08-30
EP3042915A1 (en) 2016-07-13
LT3042915T (lt) 2018-11-12
JP2017082008A (ja) 2017-05-18
HK1168603A1 (zh) 2013-01-04
DK2438083T3 (en) 2016-03-07
US20210179679A1 (en) 2021-06-17
CA2764461A1 (en) 2010-12-09
BR122020010980B1 (pt) 2021-07-06
BRPI1012924A2 (pt) 2016-04-05
US20200369735A1 (en) 2020-11-26
BRPI1012924B8 (pt) 2021-05-25
JP2015120754A (ja) 2015-07-02
MY158761A (en) 2016-11-15
PT3042915T (pt) 2018-10-18
PL2438083T3 (pl) 2016-06-30
WO2010141918A1 (en) 2010-12-09
EP2438083A4 (en) 2012-11-21
CR20110640A (es) 2012-01-30
JP5801293B2 (ja) 2015-10-28
PL3042915T3 (pl) 2019-01-31
IL216744A (en) 2016-09-29
WO2010141918A9 (en) 2013-03-28
HUE026737T2 (en) 2016-07-28
MX2011012738A (es) 2012-02-21
CN102574902B (zh) 2016-01-20
IL216744A0 (en) 2012-02-29
US9296800B2 (en) 2016-03-29
EP2438083B1 (en) 2015-12-02
EP2438083A1 (en) 2012-04-11
AU2010256426B2 (en) 2016-03-31
JP2012529429A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
CY1120817T1 (el) Παραγωγα του αμυλοειδους ρ του ορου και η παρασκευη και χρηση τους
CY1126300T1 (el) Bcma (cd269/tnfrsf17) - πρωτεϊνες δεσμευσης
EP3219725A3 (en) Dkk1 antibodies and methods of use
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
WO2018186611A3 (ko) 바이오 잉크 및 이의 제조방법
EA201491918A1 (ru) Соединения - двойные агонисты gip-glp-1 и способы
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112012013664A2 (pt) rabdovírus oncolítico
BR112012007860A2 (pt) "anticorpos siglec 15 no tratamento de doença relativa a perda óssea"
MA34004B1 (fr) Protéines de liaison à cd127
DK1871391T3 (da) Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
MX2010007443A (es) Metodo para tratar anemias de respuesta baja a eritropoyetina.
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
CO6400235A2 (es) Tensiactivos reconstituidos que tienen propiedades mejoradas
EA202092518A1 (ru) Композиции и способы лечения рака
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2014145368A3 (en) Modification and novel compositions of human secretoglobin proteins
CY1117213T1 (el) Παραγωγα του αμυλοειδους ρ του ορου και η παρασκευη και χρηση τους
WO2010121195A3 (en) Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein
EA202091631A1 (ru) Антитела к тканевому фактору, конъюгаты антитело-лекарственное средство и связанные способы
TN2012000409A1 (fr) Developpement d'un systeme de criblage des inhibiteurs de tyrosine kinase a partir de l'expression de gst-egfr chez e.coli.